CAS: 1131626-47-5

Gamitrinib-TPP is a synthetic drug that was developed to target cancer cells. It has been shown to have an activated form that binds to mitochondria and inhibits the mitochondrial membrane potential, which is necessary for the production of ATP. The drug also targets chaperones, which are proteins that assist in protein folding and regulation. Gamitrinib-TPP has been shown to inhibit stem cell-like features in cancerous cells. This drug also induces autophagy, which is a process where damaged proteins are broken down for energy production. Gamitrinib-TPP is composed of ornithine and TPP covalently bound together by a disulfide bond.

Gamitrinib TPP hexafluorophosphate is a mitochondrial-targeted HSP90 inhibitor with anticancer activity that can be used to study cancer and viral infection.